RE:Boehringer North AmericaCorrection: the testing will be for patients with various types of lung fibrosis, not just IPF. It seems there are many types?? There will be a total of 600 patients enrolled worldwide and the testing probably won't encorporate 4050 (I'm not sure). What is interesting is the size of Boehringer and their hopes for Nintedanib. It will be very interesting if Prometic 4050 does better solo than with Ninedanib in their up coming FDA trials. Could Boehringer bei trying to corner the market on the various types of lung fibrosis other than IPF?? It's complicated however I sense things are heating up!